Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02076633 | Intratumoral Administration of L19IL2/L19TNF | completed | Phase 2 | 21 | Philogen S.p.A.INDUSTRY | 1 | May 27, 2015 | clinicaltrials |
| NCT01654692 | A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma(NIBIT-M1) | completed | Phase 2 | 86 | Italian Network for Tumor BiotherapyOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00053391 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 62 | University Hospital ErlangenOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT00074230 | Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma | completed | Phase 1 / Phase 2 | 82 | University Hospital ErlangenOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT00885534 | Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma | completed | Phase 2 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT01960829 | Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study | unknown | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 1, 2015 | clinicaltrials |
| NCT00279058 | The Role of Peptide-loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2 | completed | Phase 1 / Phase 2 | 24 | Hadassah Medical OrganizationOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00089063 | Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01851408 | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 15, 2015 | clinicaltrials |
| NCT00984464 | Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | completed | Phase 2 | 14 | Oncolytics BiotechINDUSTRY | 1 | Apr 10, 2015 | clinicaltrials |
| NCT00068211 | Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma | completed | Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00072189 | A Phase II Study of UCN-01 in Metastatic Melanoma | terminated | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Mar 2, 2015 | clinicaltrials |
| NCT00412828 | A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 117 | CuraGen CorporationINDUSTRY | 1 | Feb 19, 2015 | clinicaltrials |
| NCT00086866 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery | unknown | Phase 2 | 165 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Feb 10, 2015 | clinicaltrials |
| NCT01369888 | Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jan 27, 2015 | clinicaltrials |
| NCT01386580 | An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. | completed | Phase 1 / Phase 2 | 84 | BBB-Therapeutics B.V.INDUSTRY | 4 | Jan 22, 2015 | clinicaltrials |
| NCT00755976 | Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 32 | Cancer Trials IrelandNETWORK | 1 | Dec 31, 2014 | clinicaltrials |
| NCT00089193 | Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | completed | Phase 2 | — | Craig L Slingluff, JrOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00470470 | Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00003222 | Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | 40 | University of VirginiaOTHER | 1 | Dec 19, 2014 | clinicaltrials |
| NCT00089206 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 7 | University of VirginiaOTHER | 1 | Dec 19, 2014 | clinicaltrials |
| NCT01377025 | A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma(STREAM) | unknown | Phase 2 | 200 | Prof. Dr. med. Max. E. ScheulenOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT00089219 | Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 39 | University of VirginiaOTHER | 1 | Nov 20, 2014 | clinicaltrials |
| NCT01253096 | Intratumoral Application of L19IL2 in Patients With Malignant Melanoma | completed | Phase 2 | 25 | Philogen S.p.A.INDUSTRY | 2 | Nov 20, 2014 | clinicaltrials |
| NCT00463892 | High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes | completed | Phase 2 | 200 | Redwood Regional Medical GroupOTHER | 1 | Nov 11, 2014 | clinicaltrials |
| NCT01247623 | Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | — | Oslo University HospitalOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT00462280 | Lovastatin in Treating Patients At High Risk of Melanoma | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2014 | clinicaltrials |
| NCT00299689 | Phase II Trial of Ontak With Metastatic Melanoma | completed | Phase 2 | 69 | James Graham Brown Cancer CenterOTHER | 1 | Sep 5, 2014 | clinicaltrials |
| NCT02223884 | A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy | completed | Phase 2 | 30 | Yonsei UniversityOTHER | 1 | Aug 29, 2014 | clinicaltrials |
| NCT00521053 | Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma | completed | Phase 2 | 80 | Provectus PharmaceuticalsINDUSTRY | 2 | Aug 25, 2014 | clinicaltrials |
| NCT00565721 | A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis | completed | Phase 2 | 33 | GE HealthcareINDUSTRY | 1 | Aug 18, 2014 | clinicaltrials |
| NCT00338130 | Randomised Study to Compare the Efficacy of AZD6244 vs TMZ | completed | Phase 2 | 239 | AstraZenecaINDUSTRY | 10 | Aug 13, 2014 | clinicaltrials |
| NCT00533702 | A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma | completed | Phase 2 | 106 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 1, 2014 | clinicaltrials |
| NCT00329641 | Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2014 | clinicaltrials |
| NCT01531244 | Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 18, 2014 | clinicaltrials |
| NCT01519427 | Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2014 | clinicaltrials |
| NCT00087373 | Vaccine Therapy in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00623766 | Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases | completed | Phase 2 | 99 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00671554 | Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma | terminated | Phase 1 / Phase 2 | 3 | Prisma Health-UpstateOTHER | 1 | Jun 4, 2014 | clinicaltrials |
| NCT00003274 | Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery | completed | Phase 2 | 48 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00003339 | Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | 48 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00006113 | Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma | terminated | Phase 2 | 25 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00031733 | Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma | completed | Phase 2 | 60 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00085189 | Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma | completed | Phase 2 | 42 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00184067 | Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma | terminated | Phase 2 | 23 | University of Southern CaliforniaOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT00334776 | Vaccine Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 6 | University of Southern CaliforniaOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT00669019 | Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00281957 | Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | May 20, 2014 | clinicaltrials |
| NCT02142335 | Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma | unknown | Phase 2 | 17 | California Cancer Assocaties for Research & ExcellenceOTHER | 1 | May 20, 2014 | clinicaltrials |
Data updated 23 days agoSource updated May 27, 2015source: clinicaltrials